Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials

Table 1

Baseline characteristics of the included studies.

Study, year	Patients	Sample size		Age (y)		Male (%)		Duration of DM (y)		HbA1c (%)		Trial duration (weeks)
		IDeg	IGlar	IDeg	IGlar	IDeg	IGlar	IDeg	IGlar	IDeg	IGlar
Zinman et al., 2011 [10]	T2DM	121	62	55.3 (8.7)	53.9 (8.5)	60%	60%	7.2 (4.5)	6.7 (5.0)	8.7 (1.2)	8.7 (1.1)	16
Birkeland et al., 2011 [11]	T1DM	119	59	44.5 (12.7)	45.6 (12.5)	62%	54%	21.7 (11.8)	19.1 (10.8)	8.5 (1.0)	8.3 (0.8)	16
Zinman et al., 2012 [12]	T2DM	773	257	59.3 (9.7)	58.7 (9.9)	61%	65%	9.4 (6.3)	8.6 (5.7)	8.2 (0.8)	8.2 (0.8)	52 (+52^ex)
Garber et al., 2012 [13]	T2DM	744	248	59.2 (9.1)	58.1 (10.0)	54%	54%	13.6 (7.4)	13.4 (6.9)	8.3 (0.8)	8.4 (0.9)	52 (+26^ex)
Heller et al., 2012 [14]	T1DM	472	157	42.8 (13.7)	43.7 (13.3)	59%	57%	19.1 (12.2)	18.2 (11.4)	7.7 (0.9)	7.7 (1.0)	52 (+52^ex)
Onishi et al., 2013 [20]	T2DM	289	146	58.8 (9.8)	58.1 (10.1)	55%	51%	11.8 (6.5)	11.1 (6.5)	8.4 (0.8)	8.5 (0.8)	26
Gough et al., 2013 [21]	T2DM	228	229	57.8 (9.0)	57.3 (9.4)	52%	54%	8.4 (6.7)	8.0 (5.6)	8.3 (1.0)	8.2 (0.9)	26
Mathieu et al., 2013 [22]	T1DM	329	164	43.6 (13.1)	44.1 (12.6)	60%	54%	18.7 (12.5)	18.2 (11.9)	7.7 (1.0)	7.7 (0.9)	26 (+26^ex)
Meneghini et al., 2013 [23]	T2DM	457	230	56.3 (10.1)	56.7 (8.8)	57%	48%	10.6 (6.8)	10.8 (6.4)	8.5 (1.0)	8.4 (0.9)	26
Pan et al., 2016 [16]	T2DM	555	278	55.9 (9.7)	56.6 (9.2)	54%	47%	7.6 (5.3)	8.3 (5.5)	8.3 (0.9)	8.3 (0.8)	26
DEVOTE trial, 2017 [24]	T2DM	3818	3819	64.9 (7.3)	65.0 (7.5)	63%	62%	16.6 (8.8)	16.2 (8.9)	8.4 (1.6)	8.4 (1.7)	108
Iga et al., 2017 [25]	T1DM	20	20	55 (14)	53 (18)	50%	60%	14.4 (8.6)	16.1 (8.7)	7.1 (0.9)	7.7 (0.6)	12
Warren et al., 2017 [17]	T2DM	145	145	54.7 (10.2)	55.8 (9.0)	58%	67%	12.1 (6.7)	12.1 (7.9)	8.0 (1.1)	8.3 (1.4)	16
Lane et al., 2017 [26]	T1DM	501	501	45.4 (13.7)	46.4 (14.6)	51%	57%	23.2 (13.5)	23.6 (13.4)	7.7 (1.0)	7.5 (1.0)	32
Wysham et al., 2017 [18]	T2DM	721	721	61.5 (10.7)	61.2 (10.3)	53%	53%	14.2 (8.3)	13.9 (8.0)	7.6 (1.1)	7.6 (1.1)	32

Data are shown as numbers or means (standard deviation) unless otherwise stated. IDeg: insulin degludec; IGlar: insulin glargine; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; HbA1C: hemoglobin A1c. They were crossover trials; data were from the first period. These studies had two intervention groups. Groups were combined by formulae from Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). ex: extension of trial.